Life Sciences Investor Forum

Summary by AI ^BETAClose X

Coiled Therapeutics plc announced that its Chairman will present at the Life Sciences Investor Forum on June 25, 2026, providing an opportunity for investors to engage with management. The company, listed on AIM and OTCQB, is a clinical-stage oncology firm developing precision medicines, with its lead program AO-252, a TACC3 inhibitor, currently in Phase I trials for hard-to-treat cancers. The presentation will likely cover updates on the ongoing clinical trials and the company's strategic direction.

Disclaimer*

Coiled Therapeutics PLC

19 June 2026

Coiled Therapeutics plc

("Coiled Therapeutics" or the "Company")

Life Sciences Investor Forum

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, announces that the Company's Chairman Sotirios Stergiopoulos will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on 25 June 2026.

DATE: 25 June 2026

TIME: 18:30 BST / 13.30pm Eastern Time

LINK: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5389896/coiled-therapeutics-plc-otcqb-cotxf-aim-coil

The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.

Investors can learn more about the event at www.virtualinvestorconferences.com.

-Ends-

Enquiries:

Coiled Therapeutics plc

Sotirios Stergiopoulos (Chairman)

Sridhar Vempati (CEO)

Via Harbor Access

SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker)

David Hignell / Adam Cowl / Devik Mehta (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Shard Capital Partners LLP (Joint Broker)

Damon Heath

CPS Capital Group Pty Ltd (Joint Broker)

Jason Peterson / David Valentino

+44 (0)20 4530 6926

+61 (0)8 9223 2222

Burson Buchanan (Public Relations)

Henry Harrison Topham / Jamie Hooper / Toto Berger

+44 (0)20 7466 5000

Harbor Access (US Investor Relations)

Matt Kelly / Jonathan Paterson

+1 475 477 9404

About Coiled Therapeutics plc

Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage oncology company focused on developing innovative precision therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.

About AO-252

AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.

By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, a key differentiator that may enable treatment of both primary brain tumours and brain metastases, areas of significant unmet medical need. Preclinical and early clinical observations support further evaluation of the programme's potential across multiple tumour types.

AO-252 is currently being evaluated in an ongoing Phase I open-label dose-escalation study in the United States. Early clinical observations have demonstrated encouraging anti-tumour activity and a favourable safety profile, with the Company planning to initiate dose expansion cohorts in selected indications, including prostate and ovarian cancer, during 2026.

For more information, please visit: www.coiledplc.com and follow us on LinkedIn.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END